New hope for better calcium control in rare hormone disorder

This Phase 3 trial is testing whether higher daily doses of an investigational long-acting parathyroid hormone drug (palopegteriparatide) are safe and more effective for adults with hypoparathyroidism. The study aims to help participants maintain normal blood calcium levels while reducing or stopping their need for calcium and vitamin D supplements. It will enroll 36 adults in the US who are already taking the drug at a lower dose but may need more for better control.